The European Commission has reached a preliminary agreement with the Sanofi-GSK pharmaceutical company to purchase a potential COVID-19 vaccine. This was reported by the press service of the European Commission.
The contract with Sanofi-GSK will provide an opportunity for all EU Member States to purchase the vaccine. After the safety and efficacy of the vaccine is confirmed, the European Commission is expected to procure 300 million doses on behalf of all EU member states. The Commission continues to negotiate with other vaccine manufacturers to purchase the medicines.
The European Commission is also committed to guaranteeing access to the vaccine for all Europeans who need it, anywhere in the world, not just at home.
The Commission is also ready to discuss with international partners pooling resources to jointly reserve future vaccines from companies for both their own needs and for low and middle income countries. High-income countries can act as an inclusive international group of buyers to accelerate vaccine development and maximize access to vaccines for all who need them around the world.
Since May 4, 2020, the EU has raised nearly € 16 billion in the global coronavirus response program.
On June 17, the European Commission unveiled a European strategy to accelerate the development, production and deployment of effective and safe vaccines against COVID-19.